1. Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1.
- Author
-
Kim, Jiae, Villar, Zuzana, Jobe, Ousman, Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayaphan, Sorachai, O'Connell, Robert J., Ake, Julie A., Vasan, Sandhya, Rao, Venigalla B., and Rao, Mangala
- Subjects
- *
MONOCLONAL antibodies , *HIV , *VACCINE trials , *VIRAL replication , *VACCINE development , *AIDS - Abstract
An important approach to stopping the AIDS epidemic is the development of a vaccine that elicits antibodies that block virus capture, the initial interactions of HIV-1 with the target cells, and replication. We utilized a previously developed qRT-PCR-based assay to examine the effects of broadly neutralizing antibodies (bNAbs), plasma from vaccine trials, and monoclonal antibodies (mAbs) on virus capture and replication. A panel of bNAbs inhibited primary HIV-1 replication in PBMCs but not virus capture. Plasma from RV144 and RV305 trial vaccinees demonstrated inhibition of virus capture with the HIV-1 subtype prevalent in Thailand. Several RV305 derived V2-specific mAbs inhibited virus replication. One of these RV305 derived V2-specific mAbs inhibited both virus capture and replication, demonstrating that it is possible to elicit antibodies by vaccination that inhibit virus capture and replication. Induction of a combination of such antibodies may be the key to protection from HIV-1 acquisition. • RV144 and RV305 vaccinee plasma inhibited primary HIV-1 capture by PBMCs. • One of the RV305 elicited mAb inhibited both virus capture and replication. • Vaccination can induce antibodies that inhibit HIV-1 capture and replication. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF